|
|
|
The effect of orbital radiation therapy on thyroid-associated orbitopathy complicated with dysthyroid optic neuropathy |
Yang Wang, Huifang Zhou( ), Xianqun Fan() |
| Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China |
|
|
|
|
Abstract Thyroid-associated orbitopathy (TAO) is an inflammatory autoimmune disorder. The most serious complication of TAO is dysthyroid optic neuropathy (DON), which can lead to permanent vision loss because of volume expansion in the orbital apex. Orbital radiation therapy (ORT) is an anti-inflammatory treatment used in the treatment of active TAO. Clinical studies support radiotherapy as having a modest effect on DON, and early radiotherapy may protect against disease progression to DON. Current studies suggest that radiotherapy is generally safe. However, risks still exist in some cases. The possible effects of radiotherapy on TAO, especially complicated with DON, are reviewed. The effects of radiotherapy on DON are not completely known, and evidence from standardized, prospective, and multicenter clinical trials is still lacking.
|
| Keywords
thyroid-associated orbitopathy
dysthyroid optic neuropathy
orbital radiation therapy
|
|
Corresponding Author(s):
Huifang Zhou,Xianqun Fan
|
|
Just Accepted Date: 19 April 2017
Online First Date: 16 May 2017
Issue Date: 29 August 2017
|
|
| 1 |
Rapoport B, McLachlan SM. Immunopathogenesis of Graves’ disease. In: Bahn RS. Graves' Disease. New York: Springer New York, 2015: 5–20
|
| 2 |
Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21: 168–199
|
| 3 |
Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med 2014; 53(5): 353–360
https://doi.org/10.2169/internalmedicine.53.1518
|
| 4 |
Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994; 92: 477–588
|
| 5 |
Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012; 26(3): 273–279
https://doi.org/10.1016/j.beem.2011.10.005
|
| 6 |
Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993; 38(4): 367–372
https://doi.org/10.1111/j.1365-2265.1993.tb00516.x
|
| 7 |
Perros P, Neoh C, Dickinson J. Thyroid eye disease. BMJ 2009; 338(mar06 1): b560
https://doi.org/10.1136/bmj.b560
|
| 8 |
Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121(3): 284–290
https://doi.org/10.1016/S0002-9394(14)70276-4
|
| 9 |
Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A. Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol 2003; 148(5): 491–495
https://doi.org/10.1530/eje.0.1480491
|
| 10 |
Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747–793
|
| 11 |
Garrity JA, Bahn RS. Pathogenesis of Graves’ ophthalmopathy: implications for prediction, prevention and treatment. Am J Ophthalmol 2006; 142(1): 147–153.e2
https://doi.org/10.1016/j.ajo.2006.02.047
|
| 12 |
Khalilzadeh O, Noshad S, Rashidi A, Amirzargar A. Graves’ ophthalmopathy: a review of immunogenetics. Curr Genomics 2011; 12(8): 564–575
https://doi.org/10.2174/138920211798120844
|
| 13 |
Fichter N, Guthoff RF, Schittkowski MP. Orbital decompression in thyroid eye disease. ISRN Ophthalmology 2012; 2012: 739236
|
| 14 |
Char DH. Thyroid eye disease. Br J Ophthalmol 1996; 80(10): 922–926
https://doi.org/10.1136/bjo.80.10.922
|
| 15 |
McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, Hullo AI, Kahaly G, Krassas G, Marcocci C, Marinò M, Mourits MP, Nardi M, Neoh C, Orgiazzi J, Perros P, Pinchera A, Pitz S, Prummel MF, Sartini MS, Wiersinga WM. Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007; 91(4): 455–458
https://doi.org/10.1136/bjo.2006.094607
|
| 16 |
Tsaloumas MD, Good PA, Burdon MA, Misson GP. Flash and pattern visual evoked potentials in the diagnosis and monitoring of dysthyroid optic neuropathy. Eye (Lond) 1994; 8(6): 638–645
https://doi.org/10.1038/eye.1994.159
|
| 17 |
Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, Spinelli JA. Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 1988; 95(11): 1515–1521
https://doi.org/10.1016/S0161-6420(88)32978-7
|
| 18 |
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM. Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008; 158(3): 273–285
https://doi.org/10.1530/EJE-07-0666
|
| 19 |
Kauh CY, Gupta S, Douglas RS, Elner VM, Nelson CC, Niziol LM, Kahana A. Compressive optic neuropathy and repeat orbital decompression: a case series. Ophthal Plast Reconstr Surg 2015; 31(5): 385–390
https://doi.org/10.1097/IOP.0000000000000356
|
| 20 |
Victores AJ, Takashima M. Thyroid eye disease: optic neuropathy and orbital decompression. Int Ophthalmol Clin 2016; 56(1): 69–79
https://doi.org/10.1097/IIO.0000000000000101
|
| 21 |
Alford EL, Soparkar CN. Management of the ‘tight orbit’ and associated visual loss. Curr Opin Otolaryngol Head Neck Surg 2013; 21: 417–422
|
| 22 |
Thyparampil P, Yen MT. Compressive optic neuropathy in thyroid eye disease. Int Ophthalmol Clin 2016; 56(1): 51–67
https://doi.org/10.1097/IIO.0000000000000096
|
| 23 |
.Shazli Draman M, Ludgate M. Pathogenesis of Graves’ orbitopathy. Immunol Endocr Metab Agents Med Chem 2011; 11(2): 72–82
https://doi.org/10.2174/187152211795495634
|
| 24 |
Chundury RV, Weber AC, Perry JD. Orbital radiation therapy in thyroid eye disease. Ophthal Plast Reconstr Surg 2016; 32(2): 83–89
https://doi.org/10.1097/IOP.0000000000000544
|
| 25 |
Juler FA. Diseases of the orbit acute purulent keratitis in exophthalmos goiter treated by repeated tarsorrhaphy, resection of cervical sympathetic and X -rays: retention of vision in one eye. Trans Am Ophthalmol Soc 1913; 33: 55–62
|
| 26 |
Smith TJ, Koumas L, Gagnon AM, Bell A, Sempowski GD, Phipps RP, Sorisky A. K oumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002; 87(1): 385–392
https://doi.org/10.1210/jcem.87.1.8164
|
| 27 |
Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG. Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 2008; 18(9): 983–988
https://doi.org/10.1089/thy.2007.0404
|
| 28 |
Trott KR, Kamprad F. Radiobiological mechanisms of anti-inflammatory radiotherapy. Radiother Oncol 1999; 51(3): 197–203
https://doi.org/10.1016/S0167-8140(99)00066-3
|
| 29 |
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016; 5(1): 9–26
https://doi.org/10.1159/000443828
|
| 30 |
Li Yim JF, Sandinha T, Kerr JM, Ritchie D, Kemp EG. Low dose orbital radiotherapy for thyroid eye disease. Orbit 2011; 30(6): 269–274
https://doi.org/10.3109/01676830.2011.615455
|
| 31 |
Rush S, Winterkorn JM, Zak R. Objective evaluation of improvement in optic neuropathy following radiation therapy for thyroid eye disease. Int J Radiat Oncol Biol Phys 2000; 47(1): 191–194
https://doi.org/10.1016/S0360-3016(99)00528-3
|
| 32 |
Beckendorf V, Maalouf T, George JL, Bey P, Leclere J, Luporsi E. Place of radiotherapy in the treatment of Graves’ orbitopathy. Int J Radiat Oncol Biol Phys 1999; 43(4): 805–815
https://doi.org/10.1016/S0360-3016(98)00405-2
|
| 33 |
Threlkeld A, Miller NR, Wharam M. The efficacy of supervoltage radiation therapy in the treatment of dysthyroid optic neuropathy. Orbit 1989; 8(4): 253–264
https://doi.org/10.3109/01676838909012334
|
| 34 |
Kazim M, Trokel S, Moore S. Treatment of acute Graves’ orbitopathy. Ophthalmology 1991; 98(9): 1443–1448
https://doi.org/10.1016/S0161-6420(91)32114-6
|
| 35 |
Ng CM, Yuen HK, Choi KL, Chan MK, Yuen KT, Ng YW, Tiu SC. Combined orbital irradiation and systemic steriods compared with systemic steriods alone in the management of moderate-to-severe Graves’ ophthalmopathy. Hong Kong Med J 2005; 11: 322–330
|
| 36 |
Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, Cavallacci G, Baschieri L, Pinchera A. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56(6): 1139–1144
https://doi.org/10.1210/jcem-56-6-1139
|
| 37 |
Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS. Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy. Graefes Arch Clin Exp Ophthalmol 2016; 254(5): 991–998
https://doi.org/10.1007/s00417-016-3280-7
|
| 38 |
Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomised double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 1993; 342(8877): 949–954
https://doi.org/10.1016/0140-6736(93)92001-A
|
| 39 |
Mourits MP, Kempen-Harteveld ML, García MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet 2000; 355(9214): 1505–1509
https://doi.org/10.1016/S0140-6736(00)02165-6
|
| 40 |
Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 2014; 157(6): 1299–1305
https://doi.org/10.1016/j.ajo.2014.02.044
|
| 41 |
Kim JW, Lee KH, Woo YJ, Kim J, Keum KC, Yoon JS. The effect of systemic steroids and orbital radiation for active Graves’ orbitopathy on post-decompression extraocular muscle volume. Am J Ophthalmol 2016; 171: 11–17
https://doi.org/10.1016/j.ajo.2016.08.010
|
| 42 |
Russell DJ, Dutton JJ, Baca RL. Effect of radiation therapy on intraocular pressure in patients with Graves’ orbitopathy. Orbit 2013; 32(4): 219–224
https://doi.org/10.3109/01676830.2013.788663
|
| 43 |
Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab 2004; 89(1): 15–20
https://doi.org/10.1210/jc.2003-030809
|
| 44 |
Akmansu M, Dirican B, Bora H, Gurel O. The risk of radiation-induced carcinogenesis after external beam radiotherapy of Graves’ orbitopathy. Ophthalmic Res 2003; 35(3): 150–153
https://doi.org/10.1159/000070050
|
| 45 |
Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest 2015; 38(4): 481–487
https://doi.org/10.1007/s40618-015-0257-z
|
| 46 |
Kinyoun JL, Kalina RE, Brower SA, Mills RP, Johnson RH. Radiation retinopathy after orbital irradiation for Graves’ ophthalmopathy. Arch Ophthalmol 1984; 102(10): 1473–1476
https://doi.org/10.1001/archopht.1984.01040031193016
|
| 47 |
Sánchez-Orgaz M, Grabowska A, Royo-Oreja A, Asencio-Duran M, Romero-Martin R, Arbizu-Duralde A. Optic neuropathy following orbital irradiation for Graves’ ophthalmopathy: a case report and literature review. Orbit 2012; 31(1): 30–33
https://doi.org/10.3109/01676830.2011.603458
|
| 48 |
Hurtikova K, Von Arx G, Fichter N, Gerding H. Radiation retinopathy 15 years after orbital irradiation for thyroid orbitopathy. Klin Monatsbl Augenheilkd 2016; 233(4): 508–510
https://doi.org/10.1055/s-0042-102610
|
| 49 |
Robertson DM, Buettner H, Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB. Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy. Arch Ophthalmol 2003; 121(5): 652–657
https://doi.org/10.1001/archopht.121.5.652
|
| 50 |
Gillis CC, Chang EH, Al-Kharazi K, Pickles T. Secondary malignancy following radiotherapy for thyroid eye disease. Rep Pract Oncol Radiother 2016; 21(3): 156–161
https://doi.org/10.1016/j.rpor.2016.01.001
|
| 51 |
Haenssle HA, Richter A, Buhl T, Haas E, Holzkamp R, Emmert S, Schön MP. Pigmented basal cell carcinomas 15 years after orbital radiation therapy for Graves ophthalmopathy. Arch Dermatol 2011; 147(4): 511–512
https://doi.org/10.1001/archdermatol.2011.74
|
| 52 |
Akmansu M, Dirican B, Bora H, Gurel O. The risk of radiation-induced carcinogenesis after external beam radiotherapy of Graves’ orbitopathy. Ophthalmic Res 2003; 35(3): 150–153
https://doi.org/10.1159/000070050
|
| 53 |
Hersh D, Kinnar M. Acute dysthyroid optic neuropathy exacerbated by orbital radiotherapy. Orbit 2014; 33(5): 385–387
https://doi.org/10.3109/01676830.2014.904378
|
| 54 |
Nygaard B, Specht L. Transitory blindness after retrobulbar irradiation of Graves’ ophthalmopathy. Lancet 1998; 351(9104): 725–726
https://doi.org/10.1016/S0140-6736(05)78494-4
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
